Progress in the clinical application and correlation between glucose transporter-1 and <sup>18</sup>F-FDG PET/CT imaging for non-small cell lung cancer_Journal of Biomedical Engineering

Authors：

YANG Manli ,  YOU Jinhui

Department of Nuclear Medicine, the Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan 637000, P.R.China;

Corresponding author：

Keywords：

non-small cell lung cancer; glucose transporter-1; glucose metabolism; positron emission tomography/computed tomography; ¹⁸F-fluorodeoxyglucose

DOI：

10.7507/1001-5515.202010004

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Because of the unobvious early symptoms and low 5-year survival rate, the early diagnosis and treatment is of great significance for patients with non-small cell lung cancer. Glucose transporter-1 is the most widely distributed glucose transporters in various tissue cells in the human body, whose expression in non-small cell lung cancer is closely related to the histological types, lymph node metastasis, degree of differentiation, progression and prognosis.¹⁸F-FDG PET/CT imaging, a molecular imaging diagnostic method, is based on the characteristics of glucose metabolism in malignant tumors, which has been widely applied in the cancer diagnosis, stage division, evaluation of therapeutic effects and prognosis evaluation. Glucose transporter-1 is regulated and influenced by many factors, and it is closely related to ¹⁸F-FDG PET/CT imaging. This article briefly reviews the progress in the clinical application and correlation between glucose transporter-1 and ¹⁸F-FDG PET/CT imaging for non-small cell lung cancer, in order to improve the diagnosis and treatment of lung cancer.

Citation： YANG Manli, YOU Jinhui. Progress in the clinical application and correlation between glucose transporter-1 and ¹⁸F-FDG PET/CT imaging for non-small cell lung cancer. Journal of Biomedical Engineering, 2021, 38(2): 399-404. doi: 10.7507/1001-5515.202010004 Copy

1.	Nasim F, Sabath B F, Eapen G A. Lung cancer. Med Clin North Am, 2019, 103(3): 463-473.
2.	Janssen S, Käsmann L, Rudat V, et al. Stereotactic body radiation therapy (SBRT) for recurrent non-small cell lung cancer (NSCLC). Anticancer Res, 2016, 36(2): 825-828.
3.	Herbst R S, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature, 2018, 553(7689): 446-454.
4.	Scafoglio C R, Villegas B, Abdelhady G, et al. Sodium-glucose transporter 2 is a diagnostic and therapeutic target for early-stage lung adenocarcinoma. Sci Transl Med, 2018, 10(467): eaat5933.
5.	Shewale J B, Corsini E M, Correa A M, et al. Time trends and predictors of survival in surgically resected early-stage non-small cell lung cancer patients. J Surg Oncol, 2020, 122(3): 495-505.
6.	Ceballos J, Schwalfenberg M, Karageorgis G, et al. Synthesis of indomorphan pseudo-natural product inhibitors of glucose transporters GLUT-1 and -3. Angew Chem Int Ed Engl, 2019, 58(47): 17016-17025.
7.	Lizák B, Szarka A, Kim Y, et al. Glucose transport and transporters in the endomembranes. Int J Mol Sci, 2019, 20(23): 5898.
8.	Ancey P B, Contat C, Meylan E. Glucose transporters in cancer-from tumor cells to the tumor microenvironment. FEBS J, 2018, 285(16): 2926-2943.
9.	Ma D B, Qin M M, Shi L, et al. MicroRNA-6077 enhances the sensitivity of patients-derived lung adenocarcinoma cells to anlotinib by repressing the activation of glucose transporter 1 pathway. Cell Signal, 2019, 64: 109391.
10.	Chen L, Zhou Y, Tang X, et al. EGFR mutation decreases FDG uptake in non-small cell lung cancer via the NOX4/ROS/GLUT1 axis. Int J Oncol, 2019, 54(1): 370-380.
11.	Liemburg-Apers D C, Willems P H, Koopman W J, et al. Interactions between mitochondrial reactive oxygen species and cellular glucose metabolism. Arch Toxicol, 2015, 89(8): 1209-1226.
12.	Barron C C, Bilan P J, Tsakiridis T, et al. Facilitative glucose transporters: implications for cancer detection, prognosis and treatment. Metabolism, 2016, 65(2): 124-139.
13.	Reckzeh E S, Waldmann H. Small-molecule inhibition of glucose transporters GLUT-1-4. Chembiochem, 2020, 21(1-2): 45-52.
14.	Zhao H, Sun Jian, Shao Jianshuang, et al. Glucose transporter 1 promotes the malignant phenotype of non-small cell lung cancer through integrin β1/Src/FAK signaling. J Cancer, 2019, 10(20): 4989-4997.
15.	康保洁, 石国钰, 吴立平, 等. 非小细胞肺癌组织中缺氧诱导因子1α、葡萄糖转运蛋白1及增殖细胞核抗原的表达及临床意义. 中国医药导报, 2015, 12(8): 15-17, 29.
16.	Koh Y W, Lee S J, HAN Jh, et al. PD-L1 protein expression in non-small-cell lung cancer and its relationship with the hypoxia-related signaling pathways: a study based on immunohistochemistry and RNA sequencing data. Lung Cancer, 2019, 129: 41-47.
17.	Goodwin J, Neugent M L, Lee S Y, et al. The distinct metabolic phenotype of lung squamous cell carcinoma defines selective vulnerability to glycolytic inhibition. Nat Commun, 2017, 8(1): 15503.
18.	Zhang W, Bouchard G, Yu A, et al. GFPT2-expressing cancer-associated fibroblasts mediate metabolic reprogramming in human lung adenocarcinoma. Cancer Res, 2018, 78(13): 3445-3457.
19.	张欣, 吴立平, 康保洁. 葡萄糖转运蛋白1、血管内皮生长因子及增殖细胞核抗原在非小细胞肺癌中的表达及其相关性. 中国医药导报, 2016, 13(4): 73-76.
20.	Jiang T, Zhou M L, Fan J. Inhibition of GLUT-1 expression and the PI3K/Akt pathway to enhance the chemosensitivity of laryngeal carcinoma cells in vitro. Onco Targets Ther, 2018, 11: 7865-7872.
21.	Mapelli P, Bettinardi V, Fallanca F, et al. ¹⁸F-FAZA PET/CT in the preoperative evaluation of NSCLC: comparison with ¹⁸F-FDG and immunohistochemistry. Curr Radiopharm, 2018, 11(1): 50-57.
22.	Wei R, Mao L, Xu P, et al. Suppressing glucose metabolism with epigallocatechin-3-gallate (EGCG) reduces breast cancer cell growth in preclinical models. Food Funct, 2018, 9(11): 5682-5696.
23.	Ruzzo A, Graziano F, Bagaloni I, et al. Glycolytic competence in gastric adenocarcinomas negatively impacts survival outcomes of patients treated with salvage paclitaxel-ramucirumab. Gastric Cancer, 2020, 23(6): 1064-1074.
24.	王振光, 于明明, 杨光杰, 等. 非小细胞肺癌和肺炎性病变摄取¹⁸F-FDG与Glut-1, Glut-3, HK-II表达的相关性. 中华核医学与分子影像杂志, 2018, 38(9): 605-608.
25.	Zheng H, Cui Y, Li X, et al. Prognostic significance of ¹⁸F-FDG PET/CT metabolic parameters and tumor galectin-1 expression in patients with surgically resected lung adenocarcinoma. Clin Lung Cancer, 2019, 20(6): 420-428.
26.	刘明依, 安华英, 袁伟, 等. stomatin对非小细胞肺癌细胞中葡萄糖转运蛋白1表达及定位的影响. 癌症进展, 2019, 17(4): 399-402.
27.	Kasahara N, Kaira K, Bao P, et al. Correlation of tumor-related immunity with ¹⁸F-FDG-PET in pulmonary squamous-cell carcinoma. Lung Cancer, 2018, 119: 71-77.
28.	Kaida H, Azuma K, Kawahara A, et al. Prognostic value of dual-point fluorine-18 fluorodeoxyglucose PET imaging, partial volume correction and glucose transporter-1 expression in resected nonsmall cell lung cancer patients. Nucl Med Commun, 2020, 41(1): 48-57.
29.	Cheng G, Huang H. Prognostic value of ¹⁸F-Fluorodeoxyglucose PET/computed tomography in non-small-cell lung cancer. PET Clin, 2018, 13(1): 59-72.
30.	Ichikawa T, Aokage K, Miyoshi T, et al. Correlation between maximum standardized uptake values on FDG-PET and microenvironmental factors in patients with clinical stage IA radiologic pure-solid lung adenocarcinoma. Lung Cancer, 2019, 136: 57-64.
31.	Kroenke M, Hirata K, Gafita A, et al. Voxel based comparison and texture analysis of ¹⁸F-FDG and ¹⁸F-FMISO PET of patients with head-and-neck cancer. PLoS One, 2019, 14(2): e0213111.
32.	Shen B, Huang T, Sun Y, et al. Revisit ¹⁸F-fluorodeoxyglucose oncology positron emission tomography: “systems molecular imaging” of glucose metabolism. Oncotarget, 2017, 8(26): 43536-43542.
33.	Li Xiaofeng, Du Yang, Ma Yuanyuan, et al. ¹⁸F-fluorodeoxyglucose uptake and tumor hypoxia: revisit (18)f-fluorodeoxyglucose in oncology application. Transl Oncol, 2014, 7(2): 240-247.
34.	Akhurst T. Staging of Non-Small-Cell lung cancer. PET Clin, 2018, 13(1): 1-10.
35.	Taira N, Atsumi E, Nakachi S, et al. Comparison of GLUT-1, SGLT-1, and SGLT-2 expression in false-negative and true-positive lymph nodes during the ¹⁸F-FDG PET/CT mediastinal nodal staging of non-small cell lung cancer. Lung Cancer, 2018, 123: 30-35.

1. Nasim F, Sabath B F, Eapen G A. Lung cancer. Med Clin North Am, 2019, 103(3): 463-473.
2. Janssen S, Käsmann L, Rudat V, et al. Stereotactic body radiation therapy (SBRT) for recurrent non-small cell lung cancer (NSCLC). Anticancer Res, 2016, 36(2): 825-828.
3. Herbst R S, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature, 2018, 553(7689): 446-454.
4. Scafoglio C R, Villegas B, Abdelhady G, et al. Sodium-glucose transporter 2 is a diagnostic and therapeutic target for early-stage lung adenocarcinoma. Sci Transl Med, 2018, 10(467): eaat5933.
5. Shewale J B, Corsini E M, Correa A M, et al. Time trends and predictors of survival in surgically resected early-stage non-small cell lung cancer patients. J Surg Oncol, 2020, 122(3): 495-505.
6. Ceballos J, Schwalfenberg M, Karageorgis G, et al. Synthesis of indomorphan pseudo-natural product inhibitors of glucose transporters GLUT-1 and -3. Angew Chem Int Ed Engl, 2019, 58(47): 17016-17025.
7. Lizák B, Szarka A, Kim Y, et al. Glucose transport and transporters in the endomembranes. Int J Mol Sci, 2019, 20(23): 5898.
8. Ancey P B, Contat C, Meylan E. Glucose transporters in cancer-from tumor cells to the tumor microenvironment. FEBS J, 2018, 285(16): 2926-2943.
9. Ma D B, Qin M M, Shi L, et al. MicroRNA-6077 enhances the sensitivity of patients-derived lung adenocarcinoma cells to anlotinib by repressing the activation of glucose transporter 1 pathway. Cell Signal, 2019, 64: 109391.
10. Chen L, Zhou Y, Tang X, et al. EGFR mutation decreases FDG uptake in non-small cell lung cancer via the NOX4/ROS/GLUT1 axis. Int J Oncol, 2019, 54(1): 370-380.
11. Liemburg-Apers D C, Willems P H, Koopman W J, et al. Interactions between mitochondrial reactive oxygen species and cellular glucose metabolism. Arch Toxicol, 2015, 89(8): 1209-1226.
12. Barron C C, Bilan P J, Tsakiridis T, et al. Facilitative glucose transporters: implications for cancer detection, prognosis and treatment. Metabolism, 2016, 65(2): 124-139.
13. Reckzeh E S, Waldmann H. Small-molecule inhibition of glucose transporters GLUT-1-4. Chembiochem, 2020, 21(1-2): 45-52.
14. Zhao H, Sun Jian, Shao Jianshuang, et al. Glucose transporter 1 promotes the malignant phenotype of non-small cell lung cancer through integrin β1/Src/FAK signaling. J Cancer, 2019, 10(20): 4989-4997.
15. 康保洁, 石国钰, 吴立平, 等. 非小细胞肺癌组织中缺氧诱导因子1α、葡萄糖转运蛋白1及增殖细胞核抗原的表达及临床意义. 中国医药导报, 2015, 12(8): 15-17, 29.
16. Koh Y W, Lee S J, HAN Jh, et al. PD-L1 protein expression in non-small-cell lung cancer and its relationship with the hypoxia-related signaling pathways: a study based on immunohistochemistry and RNA sequencing data. Lung Cancer, 2019, 129: 41-47.
17. Goodwin J, Neugent M L, Lee S Y, et al. The distinct metabolic phenotype of lung squamous cell carcinoma defines selective vulnerability to glycolytic inhibition. Nat Commun, 2017, 8(1): 15503.
18. Zhang W, Bouchard G, Yu A, et al. GFPT2-expressing cancer-associated fibroblasts mediate metabolic reprogramming in human lung adenocarcinoma. Cancer Res, 2018, 78(13): 3445-3457.
19. 张欣, 吴立平, 康保洁. 葡萄糖转运蛋白1、血管内皮生长因子及增殖细胞核抗原在非小细胞肺癌中的表达及其相关性. 中国医药导报, 2016, 13(4): 73-76.
20. Jiang T, Zhou M L, Fan J. Inhibition of GLUT-1 expression and the PI3K/Akt pathway to enhance the chemosensitivity of laryngeal carcinoma cells in vitro. Onco Targets Ther, 2018, 11: 7865-7872.
21. Mapelli P, Bettinardi V, Fallanca F, et al. ¹⁸F-FAZA PET/CT in the preoperative evaluation of NSCLC: comparison with ¹⁸F-FDG and immunohistochemistry. Curr Radiopharm, 2018, 11(1): 50-57.
22. Wei R, Mao L, Xu P, et al. Suppressing glucose metabolism with epigallocatechin-3-gallate (EGCG) reduces breast cancer cell growth in preclinical models. Food Funct, 2018, 9(11): 5682-5696.
23. Ruzzo A, Graziano F, Bagaloni I, et al. Glycolytic competence in gastric adenocarcinomas negatively impacts survival outcomes of patients treated with salvage paclitaxel-ramucirumab. Gastric Cancer, 2020, 23(6): 1064-1074.
24. 王振光, 于明明, 杨光杰, 等. 非小细胞肺癌和肺炎性病变摄取¹⁸F-FDG与Glut-1, Glut-3, HK-II表达的相关性. 中华核医学与分子影像杂志, 2018, 38(9): 605-608.
25. Zheng H, Cui Y, Li X, et al. Prognostic significance of ¹⁸F-FDG PET/CT metabolic parameters and tumor galectin-1 expression in patients with surgically resected lung adenocarcinoma. Clin Lung Cancer, 2019, 20(6): 420-428.
26. 刘明依, 安华英, 袁伟, 等. stomatin对非小细胞肺癌细胞中葡萄糖转运蛋白1表达及定位的影响. 癌症进展, 2019, 17(4): 399-402.
27. Kasahara N, Kaira K, Bao P, et al. Correlation of tumor-related immunity with ¹⁸F-FDG-PET in pulmonary squamous-cell carcinoma. Lung Cancer, 2018, 119: 71-77.
28. Kaida H, Azuma K, Kawahara A, et al. Prognostic value of dual-point fluorine-18 fluorodeoxyglucose PET imaging, partial volume correction and glucose transporter-1 expression in resected nonsmall cell lung cancer patients. Nucl Med Commun, 2020, 41(1): 48-57.
29. Cheng G, Huang H. Prognostic value of ¹⁸F-Fluorodeoxyglucose PET/computed tomography in non-small-cell lung cancer. PET Clin, 2018, 13(1): 59-72.
30. Ichikawa T, Aokage K, Miyoshi T, et al. Correlation between maximum standardized uptake values on FDG-PET and microenvironmental factors in patients with clinical stage IA radiologic pure-solid lung adenocarcinoma. Lung Cancer, 2019, 136: 57-64.
31. Kroenke M, Hirata K, Gafita A, et al. Voxel based comparison and texture analysis of ¹⁸F-FDG and ¹⁸F-FMISO PET of patients with head-and-neck cancer. PLoS One, 2019, 14(2): e0213111.
32. Shen B, Huang T, Sun Y, et al. Revisit ¹⁸F-fluorodeoxyglucose oncology positron emission tomography: “systems molecular imaging” of glucose metabolism. Oncotarget, 2017, 8(26): 43536-43542.
33. Li Xiaofeng, Du Yang, Ma Yuanyuan, et al. ¹⁸F-fluorodeoxyglucose uptake and tumor hypoxia: revisit (18)f-fluorodeoxyglucose in oncology application. Transl Oncol, 2014, 7(2): 240-247.
34. Akhurst T. Staging of Non-Small-Cell lung cancer. PET Clin, 2018, 13(1): 1-10.
35. Taira N, Atsumi E, Nakachi S, et al. Comparison of GLUT-1, SGLT-1, and SGLT-2 expression in false-negative and true-positive lymph nodes during the ¹⁸F-FDG PET/CT mediastinal nodal staging of non-small cell lung cancer. Lung Cancer, 2018, 123: 30-35.

Previous Article
The research advances of three dimensional porous cryogel for tissue engineering

Journal of Biomedical Engineering

Progress in the clinical application and correlation between glucose transporter-1 and ¹⁸F-FDG PET/CT imaging for non-small cell lung cancer

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Format

Content

Journal of Biomedical Engineering

Progress in the clinical application and correlation between glucose transporter-1 and 18F-FDG PET/CT imaging for non-small cell lung cancer

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Format

Content

Progress in the clinical application and correlation between glucose transporter-1 and ¹⁸F-FDG PET/CT imaging for non-small cell lung cancer